"Boldness be my friend" (Shakespeare; Cymbeline)

Blood

Volumn 118, Issue 25, 2011, Pages 6477-6478

  Altman, Jessica K ^a   Tallman, Martin S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ARSENIC TRIOXIDE; ASCORBIC ACID; RETINOIC ACID;

AGE; BLOOD; BLOOD CELL COUNT; CANCER CHEMOTHERAPY; CANCER REGISTRY; DISEASE FREE SURVIVAL; HEART ARRHYTHMIA; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAINTENANCE THERAPY; MORTALITY; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; QT PROLONGATION; QUALITY OF LIFE;

EID: 84055213205     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-11-386557     Document Type: Note

References (11)

1. Au WY, Kumana CR, Lee HKK, et al. Oral arsenic trioxide based maintenance regimens for first complete remission of acute promyelocytic leukemia: a ten-year follow up study. Blood. 2011;118(25):6535-6543.
2. Park JH, Qiao B, Panageas KS, et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood. 2011;118(5):1248-1254.
3. Lehmann S, Ravn A, Carlsson L, et al. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia. 2011;25(7):1128-1134.
4. Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. Blood. 2009;113(9):1875-1891.
5. Sanz MA, Montesinos P, Rayón C, et al. Risk-adapted treatment of acute promyelocytic leukemia based on alltrans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood. 2010;115(25):5137-5146.
6. Lo-Coco F, Avvisati G, Vignetti M, et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMAGroup. Blood. 2010;116(17):3171-3179.
7. Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010;116(19):3751-3757.
8. Gore SD, Gojo I, Sekeres MA, et al. Single cycle of arsenic trioxide based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia. J Clin Oncol. 2010;28(6):1047-1053.
9. Au WY, Kumana CR, Kou M, et al. Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia. Blood. 2003;102(1):407-408. (Pubitemid 36759684)
10. Avvisati G, Lo-Coco F, Paoloni FP, et al. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood. 2011;117(18):4716-4725.
11. Siu CW, Au WY, Yung C, et al. Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: implications for long-term cardiac safety. Blood. 2006;108(1):103-106. (Pubitemid 43990617)